Catalyst puts Therapure contract development unit up for sale: report
Canadian private equity firm Catalyst Capital Group is exploring options for Therapure Biopharma, Bloomberg reported. Catalyst has hired Wells Fargo & Co to find a buyer for the contract development and manufacturing part of its business, the story said. The Therapure unit could fetch $400 million. Catalyst is also interviewing banks to advise on an initial public offering for Therapure’s proprietary products division, Bloomberg said. Toronto-based Therapure is a maker of complex biotherapeutics, and a developer, maker and seller of its own blood and plasma-related therapeutic products. It was established in 2008 by Catalyst.
26 June 2017•1 min read
